The FDA recently instituted the "breakthrough therapy designation" as a way to more quickly get drugs for serious, unmet medical needs to the market. Today, orphan drugmaker Alexion Pharmaceuticals (ALXN) was the latest biotech to announce that its experimental hypophosphatasia drug has been granted this designation. In the following video, health-care analyst Max Macaluso discusses the importance of this news for both patients and investors.
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
What This Breakthrough Designation Means for Alexion Pharmaceuticals
This biotech's experimental hypophosphatasia drug was granted "breakthrough therapy designation" today.
Max Macaluso, Ph.D. and The Motley Fool have no position in any stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles





Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.